Case report: A patient with EGFR L861Q positive adenosquamous lung carcinoma transforming into large cell neuroendocrine cancer after treatment with Almonertinib

Case report: A patient with EGFR L861Q positive adenosquamous lung carcinoma transforming into large cell neuroendocrine cancer after treatment with Almonertinib

Almonertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is selective for both epidermal growth factor receptor tyrosine kinase inhibitor–sensitizing and T790M resistance mutations. However, resistance to the third-generation EGFR-TKIs is still inevitable. Econdar...

Full description

Bibliographic Details
Main Authors: Kele Cheng, Yong Zhu, Ran Sang, Zhongsheng Kuang, Yang Cao
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Oncology
Subjects:
Almonertinib
EGFR
mutation
neuroendocrine
large cell neuroendocrine carcinoma
LCNEC
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1453066/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2025.1453066/full

Similar Items